Amicus Therapeutics, Inc. (NASDAQ:FOLD) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Thursday.

A number of other analysts have also recently commented on the company. Zacks Investment Research cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Robert W. Baird reaffirmed an “outperform” rating and issued a $12.00 price target on shares of Amicus Therapeutics in a research note on Friday, June 30th. Bank of America Corporation lowered their target price on Amicus Therapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, May 25th. Chardan Capital reissued a “buy” rating and set a $12.50 target price on shares of Amicus Therapeutics in a research note on Thursday, June 1st. Finally, J P Morgan Chase & Co set a $13.00 target price on Amicus Therapeutics and gave the stock a “buy” rating in a research note on Monday, June 5th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $14.58.

Amicus Therapeutics (NASDAQ:FOLD) opened at 12.60 on Thursday. The firm’s market cap is $2.07 billion. Amicus Therapeutics has a 52 week low of $4.41 and a 52 week high of $14.05. The stock has a 50 day moving average of $12.41 and a 200 day moving average of $8.67.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03. The company had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $6.96 million. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. During the same period in the prior year, the business posted ($0.40) EPS. Analysts anticipate that Amicus Therapeutics will post ($1.38) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Amicus Therapeutics, Inc. (FOLD) Upgraded at BidaskClub” was reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/17/amicus-therapeutics-inc-fold-upgraded-at-bidaskclub.html.

In other news, insider Jay Barth sold 30,000 shares of the stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $10.00, for a total value of $300,000.00. Following the completion of the sale, the insider now owns 64,184 shares of the company’s stock, valued at approximately $641,840. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Hung Do sold 29,914 shares of the stock in a transaction that occurred on Friday, May 19th. The shares were sold at an average price of $8.00, for a total value of $239,312.00. Following the completion of the sale, the insider now directly owns 474,438 shares of the company’s stock, valued at approximately $3,795,504. The disclosure for this sale can be found here. 3.40% of the stock is owned by company insiders.

Several large investors have recently added to or reduced their stakes in the stock. Tokio Marine Asset Management Co. Ltd. acquired a new stake in shares of Amicus Therapeutics during the first quarter valued at about $399,000. Trexquant Investment LP acquired a new stake in shares of Amicus Therapeutics during the first quarter valued at about $496,000. UBS Asset Management Americas Inc. increased its stake in shares of Amicus Therapeutics by 71.8% in the first quarter. UBS Asset Management Americas Inc. now owns 50,674 shares of the biopharmaceutical company’s stock valued at $361,000 after buying an additional 21,174 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Amicus Therapeutics by 12.5% in the first quarter. Bank of New York Mellon Corp now owns 672,463 shares of the biopharmaceutical company’s stock valued at $4,794,000 after buying an additional 74,700 shares in the last quarter. Finally, Princeton Alpha Management LP acquired a new stake in shares of Amicus Therapeutics during the first quarter valued at about $106,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.